lncRNA MALAT1 Promotes EMT Process and Cisplatin Resistance of Oral Squamous Cell Carcinoma via PI3K/AKT/m-TOR Signal Pathway

BACKGROUND: Cisplatin (DDP) is the first-line chemotherapy agent for the treatment of oral squamous cell carcinoma (OSCC). The emergence of DDP resistance leads to diminished drug efficacy and survival benefit. lncRNA MALAT1 has been considered as one of the most important factors in OSCC. It has al...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ran, Lu, Xinxing, Yu, Riyue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231756/
https://www.ncbi.nlm.nih.gov/pubmed/32494159
http://dx.doi.org/10.2147/OTT.S251518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231756/
https://www.ncbi.nlm.nih.gov/pubmed/32494159
http://dx.doi.org/10.2147/OTT.S251518

Ejemplares similares